The purpose of this study is to evaluate the safety and efficacy of K-134 for the treatment of intermittent claudication.
Inclusion Criteria:
- Stable claudication symptoms
Exclusion Criteria:
Tucson, Arizona, United States
Little Rock, Arkansas, United States
Beverly Hills, California, United States
Los Angeles, California, United States
Sacramento, California, United States
Santa Rosa, California, United States
Vista, California, United States
Aurora, Colorado, United States
Clearwater, Florida, United States
Gulf Breeze, Florida, United States
Hialeah, Florida, United States
Jacksonville, Florida, United States
Pensacola, Florida, United States
Sarasota, Florida, United States
St. Petersburg, Florida, United States
Aurora, Illinois, United States
Chicago, Illinois, United States
Hinsdale, Illinois, United States
Indianapolis, Indiana, United States
Auburn, Maine, United States
St Louis, Missouri, United States
Oklahoma City, Oklahoma, United States
Danville, Pennsylvania, United States
Warwick, Rhode Island, United States
Charleston, South Carolina, United States
Amarillo, Texas, United States
Houston, Texas, United States
Norfolk, Virginia, United States
Richmond, Virginia, United States
Madison, Wisconsin, United States
Gatchina, Russia
Irkutsk, Russia
Moscow, Russia
Novosibirsk, Russia
Pskov, Russia
Saint Petersburg, Russia
Saratov, Russia
Smolensk, Russia
Sochi, Russia
Tomsk, Russia
Volgograd, Russia
Yaroslavl, Russia